Literature DB >> 32606316

COVID-19 meets Cystic Fibrosis: for better or worse?

Daniel Peckham1, Michael F McDermott2, Sinisa Savic2, Anil Mehta3.   

Abstract

Cystic fibrosis (CF) is one of the most common autosomal recessive life-limiting conditions affecting Caucasians. The resulting defect in the cystic fibrosis transmembrane conductance regulator protein (CFTR) results in defective chloride and bicarbonate secretion, as well as dysregulation of epithelial sodium channels (ENaC). These changes bring about defective mucociliary clearance, reduced airway surface liquid and an exaggerated proinflammatory response driven, in part, by infection. In this short article we explore the overlap in the pathophysiology of CF and COVID-19 infection and discuss how understanding the interaction between both diseases may shed light on future treatments.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32606316     DOI: 10.1038/s41435-020-0103-y

Source DB:  PubMed          Journal:  Genes Immun        ISSN: 1466-4879            Impact factor:   2.676


  14 in total

Review 1.  The Potential of Purinergic Signaling to Thwart Viruses Including SARS-CoV-2.

Authors:  Davide Ferrari; Michele Rubini; Jorge S Burns
Journal:  Front Immunol       Date:  2022-06-17       Impact factor: 8.786

2.  Cystic fibrosis improves COVID-19 survival and provides clues for treatment of SARS-CoV-2.

Authors:  Edward H Abraham; Guido Guidotti; Eliezer Rapaport; David Bower; Jack Brown; Robert J Griffin; Andrew Donnelly; Ellen D Waitzkin; Kenon Qamar; Mark A Thompson; Sukumar Ethirajan; Kent Robinson
Journal:  Purinergic Signal       Date:  2021-05-10       Impact factor: 3.765

3.  Immune transcriptomes of highly exposed SARS-CoV-2 asymptomatic seropositive versus seronegative individuals from the Ischgl community.

Authors:  Hye Kyung Lee; Ludwig Knabl; Lisa Pipperger; Andre Volland; Priscilla A Furth; Keunsoo Kang; Harold E Smith; Ludwig Knabl; Romuald Bellmann; Christina Bernhard; Norbert Kaiser; Hannes Gänzer; Mathias Ströhle; Andreas Walser; Dorothee von Laer; Lothar Hennighausen
Journal:  medRxiv       Date:  2020-09-02

4.  The global impact of SARS-CoV-2 in 181 people with cystic fibrosis.

Authors:  Elliot McClenaghan; Rebecca Cosgriff; Keith Brownlee; Susannah Ahern; Pierre-Régis Burgel; Catherine A Byrnes; Carla Colombo; Harriet Corvol; Stephanie Y Cheng; Géraldine Daneau; Alexander Elbert; Albert Faro; Christopher H Goss; Vincent Gulmans; Hector Gutierrez; Isabelle de Monestrol; Andreas Jung; Lutz Nährlich Justus; Nataliya Kashirskaya; Bruce C Marshall; Edward McKone; Peter G Middleton; Pedro Mondejar-Lopez; M Dolores Pastor-Vivero; Rita Padoan; Samar Rizvi; Rasa Ruseckaite; Marco Salvatore; Anne Stephenson; Luiz Vicente R da Silva Filho; Joel Melo; Marco Zampoli; Siobhán B Carr
Journal:  J Cyst Fibros       Date:  2020-11-04       Impact factor: 5.482

5.  First Wave of COVID-19 in French Patients with Cystic Fibrosis.

Authors:  Harriet Corvol; Sandra de Miranda; Lydie Lemonnier; Astrid Kemgang; Martine Reynaud Gaubert; Raphael Chiron; Marie-Laure Dalphin; Isabelle Durieu; Jean-Christophe Dubus; Véronique Houdouin; Anne Prevotat; Sophie Ramel; Marine Revillion; Laurence Weiss; Loic Guillot; Pierre-Yves Boelle; Pierre-Régis Burgel
Journal:  J Clin Med       Date:  2020-11-10       Impact factor: 4.241

6.  Immune transcriptomes of highly exposed SARS-CoV-2 asymptomatic seropositive versus seronegative individuals from the Ischgl community.

Authors:  Hye Kyung Lee; Ludwig Knabl; Lisa Pipperger; Andre Volland; Priscilla Furth; Keunsoo Kang; Harold Smith; Ludwig Knabl; Romuald Bellmann; Christina Bernhard; Norbert Kaiser; Hannes Gänzer; Mathias Ströhle; Andreas Walser; Dorothee Von Laer; Lothar Hennighausen
Journal:  Res Sq       Date:  2020-09-23

7.  Immune transcriptomes of highly exposed SARS-CoV-2 asymptomatic seropositive versus seronegative individuals from the Ischgl community.

Authors:  Hye Kyung Lee; Ludwig Knabl; Lisa Pipperger; Andre Volland; Priscilla A Furth; Keunsoo Kang; Harold E Smith; Ludwig Knabl; Romuald Bellmann; Christina Bernhard; Norbert Kaiser; Hannes Gänzer; Mathias Ströhle; Andreas Walser; Dorothee von Laer; Lothar Hennighausen
Journal:  Sci Rep       Date:  2021-02-19       Impact factor: 4.996

8.  Clinical characteristics of SARS-CoV-2 infection in children with cystic fibrosis: An international observational study.

Authors:  Robert Bain; Rebecca Cosgriff; Marco Zampoli; Alexander Elbert; Pierre-Régis Burgel; Siobhán B Carr; Claudio Castaños; Carla Colombo; Harriet Corvol; Albert Faro; Christopher H Goss; Hector Gutierrez; Andreas Jung; Nataliya Kashirskaya; Bruce C Marshall; Joel Melo; Pedro Mondejar-Lopez; Isabelle de Monestrol; Lutz Naehrlich; Rita Padoan; Maria Dolores Pastor-Vivero; Samar Rizvi; Marco Salvatore; Luiz Vicente Ribeiro Ferreira da Silva Filho; Keith G Brownlee; Iram J Haq; Malcolm Brodlie
Journal:  J Cyst Fibros       Date:  2020-12-03       Impact factor: 5.482

9.  Systematic review: cystic fibrosis in the SARS-CoV-2/COVID-19 pandemic.

Authors:  Hannah R Mathew; May Y Choi; Michael D Parkins; Marvin J Fritzler
Journal:  BMC Pulm Med       Date:  2021-05-20       Impact factor: 3.317

10.  Poor Respiratory Health Following Relapsing SARS-CoV-2 Infection in Children with Cystic Fibrosis.

Authors:  Nitin Dhochak; Kana Ram Jat; Kapil Dev Soni; Yudhyavir Singh; Richa Aggarwal; Rakesh Lodha; Anjan Trikha; Sushil K Kabra
Journal:  Indian J Pediatr       Date:  2022-01-28       Impact factor: 5.319

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.